Bredt David
SEC CIK 2022087 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RAPP | Rapport Therapeutics, Inc. | CSO | 393.1K | — | $2.16M | 15 | 2025-03-14 | 2026-02-19 |
Most active insiders at RAPP, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Third Rock Ventures V, L.P. | 10% | — | $34.39M |
| 2 | Ceesay Abraham | CEO, Dir | — | $6.07M |
| 3 | Yeleswaram Krishnaswamy | Chief Development Off | — | $4.46M |
| 4 | Bredt David | CSO | — | $1.36M |
| 5 | Gault Cheryl | COO | — | $906.4K |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-02-19 | 2026-02-17 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale+OE | $29.02 | -8,500 | 394.7K | -2% | -$246.6K |
| DT | 2026-02-19 | 2026-02-19 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | M - OptEx | $1.80 | +6,000 | 393.1K | +2% | +$10.8K |
| MT | 2026-01-16 | 2026-01-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale | $26.84 | -8,500 | 395.6K | -2% | -$228.2K |
| 2026-01-05 | 2025-12-31 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale | $30.05 | -6,567 | 404.1K | -2% | -$197.3K | |
| 2026-01-05 | 2025-12-31 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | A - Grant | — | -18.0K | 410.6K | -4% | — | |
| MT | 2025-12-16 | 2025-12-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale | $30.02 | -8,500 | 392.6K | -2% | -$255.2K |
| MT | 2025-11-18 | 2025-11-17 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale | $25.19 | -8,500 | 406.5K | -2% | -$214.1K |
| MT | 2025-10-16 | 2025-10-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale | $25.78 | -8,500 | 410.7K | -2% | -$219.2K |
| MT | 2025-09-17 | 2025-09-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale | $24.19 | -8,500 | 418.1K | -2% | -$205.6K |
| MT | 2025-08-18 | 2025-08-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale | $15.00 | -8,500 | 426.6K | -2% | -$127.5K |
| T | 2025-07-16 | 2025-07-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale | $14.00 | -8,500 | 435.1K | -2% | -$119.0K |
| T | 2025-06-18 | 2025-06-16 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale | $11.00 | -8,500 | 443.6K | -2% | -$93.5K |
| T | 2025-05-19 | 2025-05-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale | $9.56 | -8,500 | 452.1K | -2% | -$81.3K |
| T | 2025-04-16 | 2025-04-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale | $9.57 | -8,500 | 460.6K | -2% | -$81.3K |
| T | 2025-03-17 | 2025-03-14 | RAPP | Rapport Therapeutics, Inc. | Bredt David | CSO | S - Sale | $10.85 | -8,500 | 469.1K | -2% | -$92.2K |
Purchase Sale Sale after option exercise All abbreviations